Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2005

01-05-2005

Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs

Authors: T. E. Lans, MD, PhD, D. J. Grünhagen, MD, J. H. W. de Wilt, MD, PhD, A. N. van Geel, MD, PhD, A. M. M. Eggermont, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2005

Login to get access

Abstract

Background

Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation. Tumor necrosis factor (TNF)-α–based isolated limb perfusion (ILP) is an established alternative to achieve limb salvage but is assumed to require sufficient vasculature. Because radiotherapy is known to destroy vasculature, we wanted to evaluate retrospectively whether the outcome of ILP in patients with radiotherapy for their primary tumor nonetheless showed a benefit from TNF treatment.

Methods

We consulted a prospective database of TNF-based ILPs at the Erasmus MC–Daniel den Hoed Cancer Center in Rotterdam. Out of 342 TNF-based ILPs between 1991 and 2003, 30 ILPs were performed in 26 patients with recurrent STS in the irradiated field after prior surgery and radiotherapy. Eleven patients (42%) had multiple tumors (n = 2–20). All patients were candidates for amputation.

Results

We observed 6 complete responses (20%), 15 partial responses (50%), no change in 8 patients (27%), and progressive disease in 1 patient (3%). The median duration of response was 16 months (range, 3–56 months) at a median follow-up of 22 months (range, 3–67 months). The local recurrence rate was 45% in patients with multiple tumors and 27% in patients with single tumors. Ten patients (35%) died of systemic metastases. Limb salvage was achieved in 17 patients (65%). Regional toxicity was limited and systemic toxicity minimal.

Conclusions

TNF-based ILP can avoid amputations in most patients with recurrent extremity STS in a prior operated and irradiated field.
Literature
1.
Lienard, D, Ewalenko, P, Delmotte, JJ, Renard, N, Lejeune, FJ 1992High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcomaJ Clin Oncol105260PubMed
2.
Eggermont, AMM, Schraffordt Koops, H, Lienard, D,  et al. 1996Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trialJ Clin Oncol14265365PubMed
3.
Eggermont, AMM, Schraffordt, KH, Klausner, JM,  et al. 1996Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experienceAnn Surg22475665CrossRefPubMed
4.
Eggermont, AMM, Schraffordt Koops, H, Klausner, JM,  et al. 1999Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients (abstract)Proc Am Soc Clin Oncol11497
5.
Ginkel, RJ, Hoekstra, HJ, Eggermont, AMM, Pras, E, Schraffordt-Koops, H 1996Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalanArch Surg1316724PubMed
6.
Wieberdink, J, Benckhuysen, C, Braat, RP, Slooten, EA, Olthuis, GA 1982Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactionsEur J Cancer Clin Oncol1890510CrossRefPubMed
7.
Brennan, MF, Shiu, MH, Collin, C,  et al. 1985Extremity soft tissue sarcomasCancer Treat Symp37181
8.
Potter, DA, Kinsella, D, Gladstein, E,  et al. 1986High grade soft tissue sarcomas of the extremitiesCancer59190205
9.
Stotter, AT, A’Hearn, RP, Fisher, C, Mott, AF, Fallowfield, ME, Westbury, G 1990The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survivalCancer65111929PubMed
10.
Gustafson, P, Rööser, B, Rydholm, A 1991Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer6720836PubMed
11.
Stojadinovic, A, Jaques, DP, Leung, DH,  et al. 2001Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcomeAnn Surg Oncol850918PubMed
12.
Essner, R, Selch, M, Eilber, FR 1991Reirradiation for extremity soft tissue sarcomas. Local control and complicationsCancer6728137PubMed
13.
Janjan, NA, Crane, C, Delclos, M, Ballo, M 2002Brachytherapy for locally recurrent soft-tissue sarcomaAm J Clin Oncol25915CrossRefPubMed
14.
Pearlstone, DB, Janjan, NA, Feig, BW,  et al. 1999Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated fieldCancer J Sci Am52633PubMed
15.
Nori, D, Shupack, K, Shiu, MH, Brennan, MF 1991Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiationInt J Radiat Oncol Biol Phys20122933PubMed
16.
Catton, C, Davis, A, Bell, R,  et al. 1996Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapyRadiother Oncol4120914CrossRefPubMed
17.
Issels, RD, Abdel-Rahman, S, Wendtner, C,  et al. 2001Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II studyEur J Cancer371599608CrossRefPubMed
18.
Vrouenraets, BC, Eggermont, AMM, Hart, AA,  et al. 2001Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan aloneEur J Surg Oncol2739019CrossRefPubMed
19.
Vrouwenraets, BC, Kroon, BBR, Ogilvie, AC,  et al. 1999Absence of severe systemic toxicity after leakage controlled isolated limb perfusion with tumor necrosis factor alpha and melphalanAnn Surg Oncol640512CrossRefPubMed
20.
Stam, TC, Swaak, AJ, Vries, MR, ten Hagen, TLM, Eggermont, AMM 2000Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakageAnn Surg Oncol426875CrossRef
21.
Etten, B, Geel, AN, Wilt, JHW, Eggermont, AMM 2003Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumorsAnn Surg Oncol27327CrossRef
22.
Lans, TE, Wilt, JHW, Geel, AN, Eggermont, AMM 2002Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcomaAnn Surg Oncol910049CrossRefPubMed
23.
Eggermont, AMM, deWilt, JHW, ten Hagen, TLM 2003Current uses of isolated limb perfusion in the clinic and a model system for new strategiesLancet Oncol442937CrossRefPubMed
Metadata
Title
Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs
Authors
T. E. Lans, MD, PhD
D. J. Grünhagen, MD
J. H. W. de Wilt, MD, PhD
A. N. van Geel, MD, PhD
A. M. M. Eggermont, MD, PhD
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.03.093

Other articles of this Issue 5/2005

Annals of Surgical Oncology 5/2005 Go to the issue

Editorial

The Emergence of Modern Cancer Immunotherapy

OriginalPaper

The Value of Peritoneal Cytology as a Preoperative Predictor in Patients With Gastric Carcinoma Undergoing a Curative Resection

OriginalPaper

Tumor Progression Through Epigenetic Gene Silencing of O6−Methylguanine-DNA Methyltransferase in Human Biliary Tract Cancers

OriginalPaper

Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2

Editorial

Epigenetics and Biliary Cancer: Promise and Pitfalls

OriginalPaper

Paget’s Disease of the Breast: There Is a Role for Breast-Conserving Therapy